Scholar Rock Holding Corporation Common Stock (SRRK) is a publicly traded Healthcare sector company. As of May 20, 2026, SRRK trades at $48.35 with a market cap of $5.68B and a P/E ratio of -14.80. SRRK moved +1.68% today. Year to date, SRRK is +13.14%; over the trailing twelve months it is +53.39%. Its 52-week range spans $6.76 to $51.63. Analyst consensus is strong buy with an average price target of $60.17. Rallies surfaces SRRK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Scholar Rock slides as Q1 results highlight apitegromab BLA acceptance and site reinspection: Scholar Rock reported Q1 2026 results today and said the FDA accepted its apitegromab BLA for SMA with a Sept. 30, 2026 PDUFA action date. The company also said the FDA completed a reinspection of the Catalent Indiana fill-finish site, with a facility classification expected within 90 days.
| Metric | Value |
|---|---|
| Price | $48.35 |
| Market Cap | $5.68B |
| P/E Ratio | -14.80 |
| EPS | $-3.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $51.63 |
| 52-Week Low | $6.76 |
| Volume | 765.77K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-377.94M |
| Gross Margin | 0.00% |
15 analysts cover SRRK: 0 strong buy, 15 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $60.17.